Astec LifeSciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on July 29, 2025.
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 1.8 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Astec LifeSciences has completed the allotment of 26,69,951 equity shares under its Rights Issue, which opened on July 14, 2025 and closed on July 28, 2025. The shares were allotted at ₹890 per share, which includes a premium of ₹880 over the face value of ₹10. As a result, the company's paid-up equity share capital has increased from 1,96,11,710 shares to 2,22,81,661 shares, a rise of about 13.6%. The allotment was finalized in consultation with the registrar (MUFG Intime India) and approved by NSE as the designated stock exchange.
The expanded share base means a proportional dilution for existing shareholders who did not subscribe, while those who took up their rights maintain their stake. The successful closure of the issue brings in fresh capital (roughly ₹237.6 crore) for the company, which can support growth or reduce debt. The market price may adjust technically to reflect the new share count and the issue price level.